Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
BACKGROUND
Overactive bladder (OAB) is a series of symptoms with high prevalence in elderly people. This study was conducted using the overactive bladder symptom score (OABSS) to evaluate the efficacy of solifenacin succinate for the treatment of OAB.


METHODS
This was a prospective, multicenter, single-arm, 12-week study that enrolled 241 OAB patients. The patients received 5-10 mg/day solifenacin. Changes in OABSS, symptoms from voiding diary, perception of bladder condition (PPBC) score, international prostate symptom score (IPSS) and quality of life (QOL) were evaluated at weeks 0, 4, and 12. The relationship between OABSS and PPBC score or parameters of voiding diary was also evaluated.


RESULTS
At baseline, the mean OABSS for all patients was 9.41 ± 2.40, and was reduced significantly at week 12 (-3.76 points; 61.21%, P < 0.0001). The OABSS subscore, PPBC score, IPSS, and QOL were also significantly reduced during the study (P < 0.0001). The overall incidence of adverse events was 19.91% (44 cases). The gastrointestinal system was the most commonly affected (11.31%). Around 5.88% of the cases had adverse events related to the genitourinary system. There was a strong correlation between OABSS and urinary symptoms that was recorded in the 3-day voiding dairy.


CONCLUSIONS
We showed that solifenacin was clinically effective for relieving OAB symptoms, considering the balance between efficacy, patients' well-being, and tolerability. OABSS integrates four OAB symptoms into a single score and can be a useful tool for research and clinical practice.
Department of Urology, Beijing Hospital, Beijing 100730, China.
Ming
M
Liu
Department of Urology, Beijing Hospital, Beijing 100730, China. Email: wangjy@bjhmoh.cn.
Jianye
J
Wang
Department of Urology, Beijing Chao-Yang Hospital, Beijing 100730, China.
Yong
Y
Yang
Department of Urology, The First Clinical College of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Ruihua
R
An
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.
Jianguo
J
Wen
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Zhichen
Z
Guan
Department of Urology, Nan Fang Hospital, Guangzhou, Guandong 440100, China.
Shaobin
S
Zheng
Department of Urology, The First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030012, China.
Dongwen
D
Wang
Department of Urology, Southwest Hospital, Chongqing 400038, China.
Bo
B
Song
Department of Urology, China Rehabilitation Center, Beijing 100068, China.
Limin
L
Liao
Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
Hongqian
H
Guo
Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, China.
Jiaquan
J
Xiao
Department of Urology, Changhai Hospital of Shanghai, Shanghai 200433, China.
Yinghao
Y
Sun
Department of Urology, Ruijin Hospital Affiliated to The Shanghai Jiaotong University Medical School, Shanghai 200025, China.
Zhoujun
Z
Shen
Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Chuize
C
Kong
Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Dalin
D
He
Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Yiran
Y
Huang
Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Xiaofeng
X
Wang
Department of Urology, The General Hospital of the People's Liberation Army, Beijing 100039, China.
Xu
X
Zhang
Department of Urology, Peking Union Medical College Hospital, Beijing 100005, China.
Hanzhong
H
Li
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
Jian
J
Huang
Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.
Xiaokun
X
Zhao
Department of Urology, Wuhan Union Hospital, Wuhan, Hubei 430022, China.
Puqing
P
Zeng
Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116600, China.
Xishuang
X
Song
Department of Urology, Tongji Hospital, Tongji Medical College Huazhong University of Science, Wuhan, Hubei 430030, China.
Zhangqun
Z
Ye
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D011812:Quinuclidines / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate